Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,861 to 1,880 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RNA Editing Enzyme ADAR1 Regulates METTL3 in an Editing Dependent Manner to Promote Breast Cancer Progression via METTL3/ARHGAP5/YTHDF1 Axis. | Int J Mol Sci | 2022 | 36077054 | PubTator, text mining | PubMed |
| Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer. | Int J Mol Sci | 2022 | 36076918 | PubTator, text mining | PubMed |
| Role of TRPV1 ion channel in cervical squamous cell carcinoma genesis. | Front Mol Biosci | 2022 | 36072430 | PubTator, text mining | PubMed |
| Interaction between N6-methyladenosine and autophagy in the regulation of bone and tissue degeneration. | Front Bioeng Biotechnol | 2022 | 36072293 | PubTator, text mining | PubMed |
| CPEB2 m6A methylation regulates blood-tumor barrier permeability by regulating splicing factor SRSF5 stability. | Commun Biol | 2022 | 36064747 | PubTator, text mining | PubMed |
| Potential diabetic cardiomyopathy therapies targeting pyroptosis: A mini review. | Front Cardiovasc Med | 2022 | 36061533 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System. | J Immunol Res | 2022 | 36061307 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine RNA Methylation Regulators in the Diagnosis and Subtype Classification of Acute Myocardial Infarction. | J Immunol Res | 2022 | 36061306 | PubTator, text mining | PubMed |
| Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients. | Front Genet | 2022 | 36061188 | PubTator, text mining | PubMed |
| Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker. | Front Genet | 2022 | 36061177 | PubTator, text mining | PubMed |
| Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer. | Front Cell Dev Biol | 2022 | 36060798 | PubTator, text mining | PubMed |
| Identification and Validation of Immune Markers in Coronary Heart Disease. | Comput Math Methods Med | 2022 | 36060667 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A circRNAs identified in colorectal cancer by MeRIP sequencing. | Front Oncol | 2022 | 36059637 | PubTator, text mining | PubMed |
| Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. | Front Oncol | 2022 | 36059609 | PubTator, text mining | PubMed |
| Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer. | J Transl Med | 2022 | 36058934 | PubTator, text mining | PubMed |
| Increased expression of METTL3 in pancreatic cancer tissues associates with poor survival of the patients. | World J Surg Oncol | 2022 | 36058919 | PubTator, text mining | PubMed |
| The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway. | Mol Cancer | 2022 | 36056355 | PubTator, text mining | PubMed |
| Predictive value of drug efficacy by M6A modification patterns in rheumatoid arthritis patients. | Front Immunol | 2022 | 36052084 | PubTator, text mining | PubMed |
| Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma. | Dis Markers | 2022 | 36051357 | PubTator, text mining | PubMed |
| N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinoma. | BMC Cancer | 2022 | 36050747 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=94